ePrints

NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699

Lookup NU author(s): Dr Jill Hunter, Dr Elaine WillmoreORCiD, Professor Julie Irving, Dr Stephany Veuger, Professor barbara Durkacz

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The stress-inducible transcription factor, nuclear factor (NF)-kappa B induces genes involved in proliferation and apoptosis. Aberrant NF-kappa B activity is common in cancer and contributes to therapeutic-resistance. Poly(ADPribose) polymerase-1 (PARP-1) is activated during DNA strand break repair and is a known transcriptional co-regulator. Here, we investigated the role of PARP-1 function during NF-kappa B activation using p65 small interfering RNA (siRNA), PARP siRNA or the potent PARP-1 inhibitor, AG-014699. Survival and apoptosis assays showed that NF-kappa B p65(-/-) cells were more sensitive to ionizing radiation (IR) than p65(+/+) cells. Co-incubation with p65 siRNA, PARP siRNA or AG-014699 radio-sensitized p65(+/+), but not p65(-/-) cells, demonstrating that PARP-1 mediates its effects on survival via NF-kappa B. Single-strand break (SSB) repair kinetics, and the effect SSB repair inhibition by AG-014699 were similar in p65(+/+) and p65(-/-) cells. As preventing SSB repair did not radio-sensitize p65(-/-) cells, we conclude that radio-sensitization by AG-014699 is due to downstream inhibition of NF-kappa B activation, and independent of SSB repair inhibition. PARP-1 catalytic activity was essential for IR-induced p65 DNA binding and NF-kappa B-dependent gene transcription, whereas for tumor necrosis factor (TNF)-alpha-treated cells, PARP-1 protein alone was sufficient. We hypothesize that this stimulus-dependent differential is mediated via stimulation of the poly(ADP-ribose) polymer, which was induced following IR, not TNF-alpha. Targeting DNA damage-activated NF-kappa B using AG-014699 may therefore overcome toxicity observed with classical NF-kappa B inhibitors without compromising other vital inflammatory functions. These data highlight the potential of PARP-1 inhibitors to overcome NF-kappa B-mediated therapeutic resistance and widens the spectrum of cancers in which these agents may be utilized. Oncogene (2012) 31, 251-264; doi:10.1038/onc.2011.229; published online 27 June 2011

Publication metadata

Author(s): Hunter JE, Willmore E, Irving JAE, Hostomsky Z, Veuger SJ, Durkacz BW

Publication type: Article

Publication status: Published

Journal: Oncogene

Year: 2012

Volume: 31

Issue: 2

Pages: 251-264

Print publication date: 27/06/2011

ISSN (print): 0950-9232

ISSN (electronic): 1476-5594

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/onc.2011.229

DOI: 10.1038/onc.2011.229

Altmetrics

Funding

Share